Clinical consequences of resistant Candida infections in intensive care

International Journal of Antimicrobial Agents

Volumn 27, Issue 1, 2006, Pages 1-6

  Montravers, Philippe ^a   Jabbour, Khalil ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Antifungal treatment; Azoles; Candida; Intensive Care Unit; Prophylaxis; Resistance

Indexed keywords

ALFENTANIL; AMPHOTERICIN; ANTIFUNGAL AGENT; BENZODIAZEPINE; CALCIUM ANTAGONIST; CARBAMAZEPINE; CIMETIDINE; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; MACROLIDE; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PREDNISOLONE; RANITIDINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

CANDIDIASIS; DRUG SENSITIVITY; HUMAN; INFECTION PREVENTION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER FAILURE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW;

EID: 29944440767     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.11.002     Document Type: Short Survey

References (50)

1. H.M. Blumberg, W.R. Jarvis, and J.M. Soucie Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 2001 177 186
2. W.E. Trick, S.K. Fridkin, J.R. Edwards, R.A. Hajjeh, and R.P. Gaynes Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999 Clin Infect Dis 35 2002 627 630
3. D.J. Diekema, S.A. Messer, and A.B. Brueggemann Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study J Clin Microbiol 40 2002 1298 1302
4. O. Marchetti, J. Bille, and U. Fluckiger Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000 Clin Infect Dis 38 2004 311 320
5. M.A. Pfaller, S.A. Messer, L. Boyken, S. Tendolkar, R.J. Hollis, and D.J. Diekema Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002 J Clin Microbiol 42 2004 3142 3146
6. H. Richet, P. Roux, C. Des Champs, Y. Esnault, and A. Andremont Candidemia in French hospitals: incidence rates and characteristics Clin Microbiol Infect 8 2002 405 412
7. S. Blot, K. Vandewoude, E. Hoste, J. Poelaert, and F. Colardyn Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata J Hosp Infect 47 2001 308 313
8. K.D. Fairchild, S. Tomkoria, E.C. Sharp, and F.V. Mena Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species Pediatr Infect Dis J 21 2002 39 43
9. J. Nolla-Salas, A. Sitges-Serra, and C. Leon-Gil Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU Intensive Care Med 23 1997 23 30
10. L. Saiman, E. Ludington, and M. Pfaller Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group Pediatr Infect Dis J 19 2000 319 324
11. S.M. Swoboda, W.G. Merz, and P.A. Lipsetta Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit Surg Infect (Larchmt) 4 2003 345 354
12. A.M. Tortorano, L. Caspani, A.L. Rigoni, E. Biraghi, A. Sicignano, and M.A. Viviani Candidosis in the intensive care unit: a 20-year survey J Hosp Infect 57 2004 8 13
13. H. Dupont, C. Paugam-Burtz, and C. Muller-Serieys Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients Arch Surg 137 2002 1341 1346
14. P. Eggimann, P. Francioli, and J. Bille Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients Crit Care Med 27 1999 1066 1072
15. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk-factor of mortality in peritonitis. Crit Care Med 2006; in press.
16. P. Montravers, R. Gauzit, C. Muller, J.P. Marmuse, A. Fichelle, and J.M. Desmonts Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy Clin Infect Dis 23 1996 486 494
17. P. Sandven, H. Qvist, E. Skovlund, and K.E. Giercksky Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations Crit Care Med 30 2002 541 547
18. T. Calandra, J. Bille, R. Schneider, F. Mosimann, and P. Francioli Clinical significance of Candida isolated from peritoneum in surgical patients Lancet 2 1989 1437 1440
19. D.J. Diekema, M.A. Pfaller, and S.A. Messer In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America Antimicrob Agents Chemother 43 1999 2236 2239
20. M.A. Pfaller, R.N. Jones, G.V. Doern, H.S. Sader, R.J. Hollis, and S.A. Messer International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group J Clin Microbiol 36 1998 1886 1889
21. M.A. Pfaller, D.J. Diekema, and R.N. Jones International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program J Clin Microbiol 39 2001 3254 3259
22. J. Mora-Duarte, R. Betts, and C. Rotstein Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
23. H. Dupont, A. Bourichon, C. Paugam-Burtz, J. Mantz, and J.M. Desmonts Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31 2003 752 757
24. P.J. Eubanks, C. de Virgilio, S. Klein, and F. Bongard Candida sepsis in surgical patients Am J Surg 166 1993 617 620
25. T.J. Walsh, R.W. Finberg, and C. Arndt Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 1999 764 771
26. R.G. Luke, and J.A. Boyle Renal effects of amphotericin B lipid complex Am J Kidney Dis 31 1998 780 785
27. J.R. Wingard, M.H. White, E. Anaissie, J. Raffalli, J. Goodman, and A. Arrieta A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 2000 1155 1163
28. R. Bellmann, P. Egger, A. Djanani, and C.J. Wiedermann Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration Int J Antimicrob Agents 23 2004 80 83
29. R. Bellmann, P. Egger, and W. Gritsch Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration J Antimicrob Chemother 51 2003 671 681
30. V. Heinemann, D. Bosse, and U. Jehn Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients Antimicrob Agents Chemother 41 1997 1275 1280
31. L.B. Johnson, and C.A. Kauffman Voriconazole: a new triazole antifungal agent Clin Infect Dis 36 2003 630 637
32. C. Robatel, M. Rusca, C. Padoin, O. Marchetti, L. Liaudet, and T. Buclin Disposition of voriconazole during continuous veno-venous haemodiafiltration in a single patient J Antimicrob Chemother 54 2004 269 270
33. S. Hadley, W.W. Lee, R. Ruthazer, and S.A. Nasraway Jr. Candidemia as a cause of septic shock and multiple organ failure in nonimmunocompromised patients Crit Care Med 30 2002 1808 1814
34. S.L. Buijk, I.C. Gyssens, J.W. Mouton, H.A. Verbrugh, D.J. Touw, and H.A. Bruining Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function Intensive Care Med 27 2001 115 121
35. K. Yagasaki, S. Gando, and N. Matsuda Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration Intensive Care Med 29 2003 1844 1848
36. F. Pea, and M. Furlanut Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions Clin Pharmacokinet 40 2001 833 868
37. S. Perea, and T.F. Patterson Antifungal resistance in pathogenic fungi Clin Infect Dis 35 2002 1073 1080
38. T.R. Rocco, S.E. Reinert, and H.H. Simms Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance Arch Surg 135 2000 160 165
39. J.R. Wingard, W.G. Merz, M.G. Rinaldi, T.R. Johnson, J.E. Karp, and R. Saral Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole N Engl J Med 325 1991 1274 1277
40. J.R. Wingard, W.G. Merz, M.G. Rinaldi, C.B. Miller, J.E. Karp, and R. Saral Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients Antimicrob Agents Chemother 37 1993 1847 1849
41. J.R. Wingard Importance of Candida species other than C. albicans as pathogens in oncology patients Clin Infect Dis 20 1995 115 125
42. J.A. Sangeorzan, S.F. Bradley, and X. He Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance Am J Med 97 1994 339 346
43. X. He, R.N. Tiballi, L.T. Zarins, S.F. Bradley, J.A. Sangeorzan, and C.A. Kauffman Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus Antimicrob Agents Chemother 38 1994 2495 2497
44. J.A. Savino, N. Agarwal, P. Wry, A. Policastro, T. Cerabona, and L. Austria Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients J Trauma 36 1994 20 25
45. G.J. Slotman, and K.W. Burchard Ketoconazole prevents Candida sepsis in critically ill surgical patients Arch Surg 122 1987 147 151
46. A.Z. Ables, N.A. Blumer, G.T. Valainis, M.T. Godenick, D.K. Kajdasz, and Y.Y. Palesh Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial Infect Dis Clin Pract 9 2000 169 175
47. R.K. Pelz, C.W. Hendrix, and S.M. Swoboda Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients Ann Surg 233 2001 542 548
48. J. Garbino, D.P. Lew, J.A. Romand, S. Hugonnet, R. Auckenthaler, and D. Pittet Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination Intensive Care Med 28 2002 1708 1717
49. S.D. Kicklighter, S.C. Springer, T. Cox, T.C. Hulsey, and R.B. Turner Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant Pediatrics 107 2001 293 298
50. Jury's recommendations. Consensus Conference. Management of invasive aspergillosis and candidiasis in adults. Ann Fr Anesth Réanim 2004;23.